ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
William R. Burfeind
Eric Toloza
Rebecca P. Petersen
David H. Harpole, Jr
Thomas A. D’Amico
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lemaire, A.
Right arrow Articles by D’Amico, T. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lemaire, A.
Right arrow Articles by D’Amico, T. A.
Related Collections
Right arrow Trachea and bronchi

Ann Thorac Surg 2005;80:434-438
© 2005 The Society of Thoracic Surgeons

Original article: General thoracic

Outcomes of Tracheobronchial Stents in Patients With Malignant Airway Disease

Anthony Lemaire, MD, William R. Burfeind, MD, Eric Toloza, MD, PhD, Scott Balderson, PA-C, Rebecca P. Petersen, MD, David H. Harpole, Jr, MD, Thomas A. D’Amico, MD *

Division of Thoracic Surgery, Duke University Medical Center, Durham, North Carolina

Accepted for publication February 23, 2005.

* Address reprint requests to Dr D’Amico, Duke University Medical Center, Box 3496, Durham, NC 27710 (Email: damic001{at}mc.duke.edu).

Presented at the Fifty-first Annual Meeting of the Southern Thoracic Surgical Association, Cancun, Mexico, Nov 2–4, 2004.

BACKGROUND: Malignant central airway obstruction is difficult to manage and is associated with poor outcome. We sought to identify the short (<30 days) and intermediate (>30 days) benefits and risks of tracheobronchial stents in patients with malignant airway disease.

METHODS: Two hundred and twenty-five tracheobronchial stents were placed in 172 patients for benign (n = 32) and malignant (n = 140) disease from January 1, 1997, to May 31, 2003. The records of the patients with malignant disease were retrospectively analyzed to determine complication rate, reintervention rate, and survival. The malignant diagnoses included nonsmall cell cancer, small cell cancer, esophageal cancer, and metastatic disease.

RESULTS: There were 172 stents placed in 140 patients with malignant disease, with no intraoperative mortality. The mean follow-up period was 142 ± 12 days. There were 23 complications, including tumor ingrowth (n = 9), excessive granulation tissue (n = 7), stent migration (n = 5), and restenosis (n = 2). Five of the complications occurred during the short-term period (<30 days) with the remaining complications (n = 18) occurring after 30 days. The complications required interventions including laser debridement (n = 14), dilation (n = 4), and stent removal (n = 5).

CONCLUSIONS: Tracheobronchial stents offer minimally invasive palliative therapy for patients with unresectable malignant central airway obstruction. The benefit of airway stents is particularly seen in the short-term period where they provide symptomatic improvement and have low complication risk. The major impediment is excessive granulation tissue and tumor ingrowth, which occur primarily after 30 days.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
C. S. Chin, V. Litle, J. Yun, T. Weiser, and S. J. Swanson
Airway Stents
Ann. Thorac. Surg., February 1, 2008; 85(2): S792 - S796.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The Society of Thoracic Surgeons.